Skip to content

META English logo

Main menu
    • About us
      • Vision, mission and values
      • Diversity, equity & inclusion
      • Executive Leadership Team
      • Global Leaders
      • Board of Directors
      • Our leaders
    • Environmental, social & governance
    • Policies & positions
    • Suppliers
    • Media
    • Press releases
    • Women’s Health Accelerator
    • Rahet Bally x Organon
    • Investor relations overview
    • SEC filings
  • Join our team

Contact Us

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Entrepreneurs Triumph at Organon and Flat6Lab’s Women’s Health Accelerator Demo Day

Save Print

October 18, 2024 12:16 pm EDT

  • The Demo Day, held in collaboration with Flat6Labs, marked the closing of the second edition of the Women’s Health Accelerator Program
  • Eight start-ups from the UAE, Lebanon, Egypt, Tunisia, and Poland presented their women’s health solutions to a panel of industry experts

Dubai, United Arab Emirates – 15 October 2024: Eight pioneering start-ups who participated in the second edition of the Women’s Health Accelerator Program, attended Organon’s Demo Day during the ‘Expand North Star’ event at Dubai Harbor, hosted by GITEX Global. This initiative, a collaboration between Organon, a leading global healthcare company dedicated to improving women’s health, and Flat6Labs, MENA’s premier seed and early-stage venture capital firm, aims to address unmet women’s healthcare needs across the region. This year’s edition was launched on March 8, in celebration of International Women’s Day.

The Demo Day saw shortlisted startups from the UAE, Lebanon, Egypt, Poland and Tunisia pitch solutions that exemplify the remarkable innovation and potential impact on women’s health that the accelerator program aims to foster. Over the course of the program, these start-ups have benefitted from an array of resources provided by the program, including strategic mentorship, entrepreneurship-focused business training, subject matter one-to-one sessions, and a multitude of services from partners.

In the session, the shortlisted start-ups pitched their innovations to an esteemed judging panel comprising Dina El Shenoufy, Chief Investment Officer at Flat6Labs; Ramy Koussa, Associate Vice President of META at Organon; Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi; and Lyndal Cordaro, Head of Nursing at King’s College Hospital London – UAE.

iYoni, an innovative mobile app offering precise AI-based fertility predictions, automated lab test assessments, and advice from fertility experts, took first-place and received a prize of 15,000 USD. In her pitch, Katarzyna Goch, CEO of iYoni, outlined her ambitious plans to expand to the UAE market.

Taking the second-place prize of 10,000 USD was Noor Jaber, CEO of Nawat from Lebanon, a digital platform offering holistic reproductive health education and breaking the taboo around women’s health issues in the region. In third place and receiving a 5,000 USD prize was Banet from Tunisia, an app that empowers women with reliable health information and provides women with direct access to healthcare professionals for their health and wellness needs.

Among the other innovative projects presented at the event was Yotto from the UAE, a platform optimizing female athletes’ performance through hormonal monitoring, addressing a significant gap in sports science. Another UAE-based startup, Mamahood, introduced a comprehensive support system for women during fertility, pregnancy, and motherhood, offering a 24/7 live chat with doctors and a supportive community. Me-Now, also from the UAE, aims to guide women through perimenopause and menopause, ensuring they receive the necessary support and understanding during these transitions.

In addition, several other startups showcased their groundbreaking solutions, addressing critical subjects in women’s health in the region. InBalance, an initiative from Lebanon, outlined their app that offers personalized AI-powered treatments for PCOS patients, aiming to naturally improve health outcomes. The Aziza App from Egypt, tailored specifically for Egyptian women, was also presented, providing meaningful menstrual health tracking and management.

Speaking at the opening session of the Demo Day, Ramy Koussa, Associate Vice President of META at Organon, said, “The Women’s Health Accelerator Program has been a remarkable journey of innovation and collaboration. We are incredibly proud of the startups that participated and the groundbreaking solutions they have developed. Inspired by the success of this program, we were thrilled to launch the second edition, aiming to enhance our support by empowering women economically and fostering new ideas that enhance women’s health. At Organon, we believe that addressing women’s health needs is essential for building resilient and thriving communities. This program is a testament to our commitment to fostering innovation that directly impacts women’s lives.”

Dina El Shenoufy, Chief Investment Officer at Flat6Labs, said, “Supporting founders in the Femtech industry is critical to advancing -not only women’s healthcare- but also driving broader economic growth. Through programs like Women’s Health Accelerator, we ensure that female founders receive the tools and resources they need to succeed and make a meaningful impact on women’s lives. We are proud of all the startups who participated in this program; they showed us how the next generation of female leaders are focused on addressing the unmet needs in women’s health.”

Katarzyna Goch, CEO of the winning start-up iYoni, commented, “Participating in the women’s health accelerator program was an outstanding experience. From the very beginning, we connected with experts who provided invaluable advice that I can implement both now and in the future.” The accelerator program, initiated shortly after Organon’s expansion into the region, represents a pioneering ESG initiative that underscores Organon’s dedication to addressing women’s health needs. This program, aligned with Organon’s mission to enhance the lives of women and girls through improved health outcomes, was meticulously crafted to bolster female entrepreneurship and support digital health startups.

What can we help you find?

Search for:
META English logo

Company

  • About us
  • Our leaders
  • Environmental, social & governance

Resources

  • Patient resources
  • Investor relations
  • Media

Contact us

  • Contact Us
  • Contact information
  • Global locations
  • Forward-Looking Statement
  • cookie policy
  • Privacy
  • Terms of Use
  • Sitemap
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept